Physician profile
Sumer Baroud
NPI 1912647017
$3,134.98
in general payments reported to CMS, 2019-2025
19 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $297 · 2023: $564 · 2024: $909 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.82 | 2022-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $489.91 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $290.81 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $256.20 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $243.52 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.41 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $187.20 | 2023-2024 | Vtama |
| Ucb, INC. | $133.46 | 2023 | |
| Mallinckrodt Hospital Products INC. | $127.21 | 2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.00 | 2022 | |
| Arcutis Biotherapeutics, INC. | $113.31 | 2023-2025 | Zoryve |
| Blueprint Medicines Corporation | $103.73 | 2025 | |
| Galderma Laboratories, L.P. | $75.00 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.96 | 2024-2025 | Spevigo |
| Janssen Biotech, INC. | $57.08 | 2025 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.58 | 2024 | |
| Chiesi USA, INC. | $27.22 | 2024 | Filsuvez |
| Lnhc, INC | $26.67 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $17.89 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumer Baroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.